Under the Paperwork Reduction Act of 1995, no persons are required to resp and to a collection of information unless it contains a valid CMB control number.

	Application Number		10595347	
INFORMATION DIGGI COURT	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Boris		s Pervan	
(Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Number	r	PERV 0101 PUSA	

				U.S.	PATENTS	Remove
Examiner Initial*	r Cite No Patent Number Kind Code1 Issue Date Name of Patentee or As		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	3667378	A	1972-06-06	Picard et al	
	2	3750527	A	1973-08-07	Heinemann	
	3	3513778	A	1970-05-26	Heinemann	
	4	5373790	A	1994-12-20	Chemiere et al	
	5	3175055	A	1965-03-23	Klapheke	
If you wis	n to a	dd additional U.S. Pater			lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wis	n to a	l dd additional U.S. Publi:	hed Ap	plication citation	n information please click the Ad	d button. Add
				FOREIGN PAT	TENT DOCUMENTS	Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Fram

Application Number		10595347
Filing Date		
First Named Inventor	Boris	Pervan
Art Unit		
Examiner Name		
Attorney Docket Numb	er	PERV 0101 PUSA

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Appl	e of Patentee or licant of cited ument	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	Ts
	1	2691799	FR	A	1993-12-03	Giat	Ind Sa		
If you wish	h to a	dd additional Foreign	Patent Documer	nt citation	information p	lease	click the Add butto	n Add	_
			NON-PAT	ENT LITE	RATURE DO	CUME	ENTS	Remove	
Examiner Initials*	miner Cite Include name of the author (in CAPITAL LETTERS), itile of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catabig, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Тs			
	1								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE									
Examiner	Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

See Kind Codes of USPTO Platent Documents at sweru(SPTO_GOV) or MPEP 901.04. Enter office that issued the document, by the how-left or (WIPO) Standard 57.3.) For Lapraesee planet fourments, the schication of the year of the region or preceded the service of the center of the planet document. A found of coursent by the appropriate symbols as andicated on the document under WIPO Standard 57.16 if possible. Speciation is to place a check mark here if English supraugate Precision is adstanced.

| Application Number | 10595347 | Filing Date | The Number | The

CERTIFICATION STATEMENT

Diagra con	37	CER .	1 97	and	1 08	to make	a the	annronniate	selection(s):	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/John E. Nemazı/	Date (YYYY-MM-DD)	2006-07-06
Name/Print	John E. Nemazi	Registration Number	30876

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.